[go: up one dir, main page]

AR054632A1 - ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN - Google Patents

ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN

Info

Publication number
AR054632A1
AR054632A1 ARP060102992A ARP060102992A AR054632A1 AR 054632 A1 AR054632 A1 AR 054632A1 AR P060102992 A ARP060102992 A AR P060102992A AR P060102992 A ARP060102992 A AR P060102992A AR 054632 A1 AR054632 A1 AR 054632A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
heterocyclyl
alkyl
aryl
alkylthio
Prior art date
Application number
ARP060102992A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR054632A1 publication Critical patent/AR054632A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Utiles como medicamentos en enfermedades cardiovasculares como así también a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1) o una sal aceptable para uso farmacéutico del mismo: donde R1 representa R6OC(O), R7C(O), R16SC(O), R17S, R18C(S) o un grupo de formula (2), R2 representa H, CN, halogeno (F, Cl, Br, I), NO2, alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con OH, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I); además R2 representa alcoxi C1-12 opcionalmente sustituido con uno o más átomos de halogeno (F, Cl, Br, I); además R2 representa cicloalquilo C3-6, hidroxialquilo C1-12, alquil C1-12C(O), alquiltio C1-12C(O), alquil C1-12C(S), alcoxi C1-12C(O), cicloalcoxi C3-6, arilo, arilC(O), arilalquil C1-12C(O), heterociclilo, heterociclilC(O), heterociclilalquil C1-12C(O), alquilsulfinilo C1-12, alquilsulfonilo C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinilo, arilsulfonilo, ariltio, arilalquiltio C1-12, arilalquilsulfinilo C1-12, arilalquilsulfonilo C1-12, heterociclilalquiltio C1-12, heterociclilalquilsulfinilo C1-12, heterociclilalquilsulfonilo C1-12, cicloalquil C3-6alquiltio C1-12, cicloalquil C3-6 alquilsulfinilo C1-12, cicloalquil C3-6alquilsulfonilo C1-12, o un grupo de formula NRa(2)Rb(2) donde Ra(2) y Rb(2) representan en forma independiente H, alquilo C1-12, alquil C1-12C(O) o Ra(2) y Rb(2) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; además, R1 + R2 juntos (con dos átomos de carbono del anillo de piridina) pueden formar una lactona cíclica de 5 o 6 miembros; R3 representa H, CN, NO2, halogeno (F, CI, Br, I), alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con OH, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I); además R3 representa alcoxi C1-12 opcionalmente sustituido con uno o más átomos de halogeno (F, CI, Br, I); además R3 representa cicloalquilo C3-6, hidroxialquilo C1-12, alquil C1-12C(O), alquiltio C1-12C(O), alquil C1-12C(S), alcoxi C1-12C(O), cicloalcoxi C3-6, arilo, arilC(O), arilalquil C1-12C(O), heterociclilo, heterociclilC(O), heterociclilalquil C1-12C(O), alquilsulfinilo C1-12, alquilsulfonilo C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinilo, arilsulfonilo, ariltio, arilalquiltio C1-12, arilalquilsulfinilo C1-12, arilalquilsulfonilo C1-12, heterociclilalquiltio C1-12, heterociclilalquilsulfinilo C1-12, heterociclilalquilsulfonilo C1-12, cicloalquil C3-6alquiltio C1-12, cicloalquil C3-6alquilsulfinilo C1-12, cicloalquil C3-6alquilsulfonilo C1-12 o un grupo de formula NRa(3)Rb(3) donde Ra(3) y Rb(3) representan en forma independiente H, alquilo C1-12, alquil C1-12C(O) o Ra(3) y Rb(3) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; R4 representa H, CN, NO2, halogeno (F, CI, Br, I), alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con OH, COOH, alcoxicarbonilo C1-6, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I); además R4 representa cicloalquilo C3-6, hidroxialquilo C1-12, alquil C1-12C(O), alquilcicloalquilo C1-12, alcoxi C1-12 donde el grupo alcoxi puede estar opcionalmente sustituido con uno o más átomos de halogeno (F, CI, Br, I), OH y/o COOH y/o alcoxicarbonilo C1-6; además R4 representa alquiltio C1-12C(O), alquil C1-12C(S), alcoxi C1-12C(O), cicloalcoxi C3-6, arilo, arilC(O), arilalquil C1-12C(O), heterociclilo, heterociclilC(O), heterociclilalquil C1-12C(O), alquilsulfinilo C1-12, alquilsulfonilo C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinilo, arilsulfonilo, ariltio, arilalquiltio C1-12, ariIalquilsuIfinilo C1-12, arilalquilsulfonilo C1-12, heterociclilalquiltio C1-12, heterociclilalquilsulfinilo C1-12, heterociclilalquilsulfonilo C1-12, cicloalquil C3- 6alquiltio C1-12, cicloalquil C3-6alquilsulfinilo C1-12, cicloalquil C3-6alquilsulfonilo C1-12 o un grupo de formula NRa(4)Rb(4) donde Ra(4) y Rb(4) representan en forma independiente H, alquilo C1-12, alquil C1-12C(O) o Ra(4) y Rb(4) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; Z representa O o esta ausente; R5 representa H o alquilo C1-12; R6 representa alquilo C1-12 opcionalmente interrumpido por oxígeno, (con la condicion de que cualquier oxígeno debe estar al menos a 2 átomos de carbono de distancia del oxígeno del éster que conecta el grupo R6) y/u opcionalmente sustituido con OH, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I); además R6 representa cicloalquilo C3-6, hidroxialquilo C2-12, arilo o heterociclilo; R7 representa alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con OH, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I), además R7 representa cicloalquilo C3-6, hidroxialquilo C1-12, arilo o heterociclilo; R8 representa H, alquilo C1-12 opcionalmente interrumpido con oxígeno y/u opcionalmente sustituido con arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, C, Br, I); además R8 representa cicloalquilo C3-6, hidroxialquilo C1-12, alcoxi C1-12, cicloalcoxi C3-6, arilo, heterociclilo, alquilsulfinilo C1-12, alquilsulfonilo C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinilo, arilsulfonilo, ariltio, arilalquiltio C1-12, ariIalquilsulfiniIo C1-12, arilalquilsulfonilo C1-12, heterociclilalquiltio C1-12, heterociclilalquilsulfinilo C1-12, heterociclilalquilsulfonilo C1-12, cicloalquil C3-6alquiltio, C1-12, cicloalquil C3- 6alquilsulfinilo C1-12 o cicloalquil C3-6alquilsulfonilo C1-12; R14 representa H, OH con la condicion de que el grupo OH debe estar al menos a 2 átomos de carbono de distancia de cualquier heteroátomo en el anillo/sistema anular B, alquilo C1-12 opcionalmente interrumpido por oxígeno, y/u opcionalmente sustituido con uno o más de OH, COOH y COORe; donde Re representa arilo, cicloalquilo, heterociclilo o alquilo C1-12 opcionalmente sustituido con uno o más átomos de halogeno (F, CI, Br, I), OH, arilo, cicloalquilo y heterociclilo; además R14 representa arilo, heterociclilo, uno o más átomos de halogeno (F, CI, Br, I), cicloalquilo C3-6, hidroxialquilo C1-12, alcoxi C1-12, cicloalcoxi C3-6, arilo, heterociclilo, alquilsulfinilo C1-12, alquilsulfonilo C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinilo, arilsulfonilo, ariltio, arilalquiltio C1-12, arilalquilsulfinilo C1-12, arilalquilsulfonilo C1-12, heterociclilalquiltio C1-12, heterociclilalquilsulfinilo C1-12, heterociclilalquilsulfonilo C1-12, cicloalquil C3-6alquiltio C1-12, cicloalquil C3-6alquilsulfinilo C1-12 o cicloalquil C3-6alquilsulfonilo C1-12, un grupo de formula Ra(14) y Rb(14) donde Ra(14) y Rb(14) representan en forma independiente H, alquilo C1-12, alquil C1-12C(O), alcoxi C1-12C(O) o Ra(14) y Rb(14) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; R15 representa H, OH con la condicion de que el grupo OH debe estar al menos a 2 átomos de carbono de distancia de cualquier heteroátomo en el anillo/sistema anular B, alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con uno o más de OH, COOH y COORe; donde Re representa arilo, cicloalquilo, heterociclilo o alquilo opcionalmente sustituido con uno o más átomos de halogeno (F, CI, Br, I), OH, arilo, cicloalquilo y heterociclilo; además R15 representa arilo, heterociclilo, uno o más átomos de halogeno (F, CI, Br, I), cicloalquilo C3-6, hidroxialquilo C1-12, alcoxi C1-12, cicloalcoxi C3-6, arilo, heterociclilo, alquilsulfinilo C1-12, alquilsulfonilo C1-12, alquiltio C1-12, cicloalquiltio C3-6, arilsulfinilo, arilsulfonilo, ariltio, arilalquiltio C1-12, arilalquilsulfinilo C1-12, arilalquilsulfonilo C1-12, heterociclilalquiltio C1-12, helerociclilalquilsulfinilo C1-12, heterociclilalquilsulfonilo C1-12, cicloalquil C3-6alquiltio C1-12, cicloalquil C3-6alquilsulfinilo C1-12, cicloalquil C3-6alquilsulfonilo C1-12 o un grupo de formula NRa(15)Rb(15) donde Ra(15) y Rb(15) representan en forma independiente H, alquilo C1-12, alquil C1-12C(O), alcoxi (C1-12C(O) o Ra(15) y Rb(15) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; R16 representa alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con OH, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I), además R16 representa cicloalquilo C3-6, hidroxialquilo C1-12, alcoxi C1-12, cicloalcoxi C3-6, arilo o heterociclilo; R17 representa alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con OH, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I), además R17 representa cicloalquilo C3-6, hidroxialquilo C1-12, alcoxi C1-12, cicloalcoxi C3-6, arilo o heterociclilo; R18 representa alquilo C1-12 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido con OH, arilo, cicloalquilo, heterociclilo o uno o más átomos de halogeno (F, CI, Br, I), además R18 representa cicloalquilo C3-6, hidroxialquilo C1-12, alcoxi C1-12, cicloalcoxi C3-6, arilo o heterociclilo; Rc representa un grupo alquileno C1-4, un grupo oxoaIquileno C1-4, un grupo alquilenoxi C1-4 o un grupo oxialquileno C1-4 no sustituido o monosustituido o polisustituido, donde cualquiera de los sustituyentes se seleccionan cada uno en forma individual e independiente de alquilo C1-4, alcoxilo C1-4, oxialquilo C1-4, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-6, carboxilo, carboxialquilo C1-4, arilo, heterociclilo, nitro, ciano, halogeno (F, CI, Br, I), hidroxilo, NRa(Rc)Rb(Rc) donde Ra(Rc) y Rb(Rc) en forma individual e independiente entre sí representan hidrogeno, alquilo C1-4 o Ra(Rc) y Rb(Rc) junto con el átomo de nitrogeno representan piperidina, pirrolidina, azetidina o aziridina; además Rc representa imino (-NH-), imino
ARP060102992A 2005-07-13 2006-07-12 ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN AR054632A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0501663 2005-07-13
SE0502354 2005-10-24

Publications (1)

Publication Number Publication Date
AR054632A1 true AR054632A1 (es) 2007-07-04

Family

ID=37637403

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102992A AR054632A1 (es) 2005-07-13 2006-07-12 ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN

Country Status (15)

Country Link
US (1) US20080312208A1 (es)
EP (1) EP1904474A4 (es)
JP (1) JP2009501216A (es)
KR (1) KR20080039405A (es)
AR (1) AR054632A1 (es)
AU (1) AU2006267148A1 (es)
CA (1) CA2614726A1 (es)
EC (1) ECSP088140A (es)
IL (1) IL188293A0 (es)
MX (1) MX2008000470A (es)
NO (1) NO20076682L (es)
RU (1) RU2008101924A (es)
TW (1) TW200726758A (es)
UY (1) UY29667A1 (es)
WO (1) WO2007008140A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542641A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類縁体
US20080027103A1 (en) * 2006-07-04 2008-01-31 Astrazeneca Ab Novel Crystalline Forms 1
WO2008085119A1 (en) * 2007-01-12 2008-07-17 Astrazeneca Ab New pyridine analogues viii 518
CL2008000092A1 (es) * 2007-01-12 2008-09-05 Astrazeneca Ab Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.
AU2008203953A1 (en) * 2007-01-12 2008-07-17 Astrazeneca Ab Pyridine compounds and their use as P2Y12 antagonists.
CL2008000090A1 (es) * 2007-07-13 2009-01-16 Astrazeneca Ab Compuestos derivados de piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso como inhibidores del receptor p2y 12 para tratar un trastorno de agragacion de plaquetas.
AR072697A1 (es) * 2008-07-07 2010-09-15 Astrazeneca Ab Compuestos de piridina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastorno de agregacion plaquetaria
AR074628A1 (es) * 2008-07-07 2011-02-02 Astrazeneca Ab Derivados de piridina 2- amino-6-alquil sustituidos utiles como inhibidores de p2y12 308
JP2014051434A (ja) * 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
CN103483274B (zh) * 2013-09-25 2016-03-09 江苏快达农化股份有限公司 一种制备苄嘧磺隆的方法
CA2994924A1 (en) * 2015-08-06 2017-02-09 Ube Industries, Ltd. Substituted guanidine derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
EP1257550B1 (en) * 2000-02-04 2005-11-16 Portola Pharmaceuticals, Inc. Platelet adp receptor inhibitors
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
AR037097A1 (es) * 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
ES2610611T3 (es) * 2002-01-18 2017-04-28 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
MXPA06003625A (es) * 2003-10-03 2006-08-11 Portola Pharm Inc Isoquinolinonas sustituidas.
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
WO2005056354A2 (en) * 2003-12-03 2005-06-23 Gedeon Anthony A Method of resisting contaminant build up and oxidation of vehicle surfaces and other surfaces
AU2005267289A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
RU2007129779A (ru) * 2005-01-06 2009-02-20 Астразенека Аб (Se) Новые соединения пиридина
CN101511815A (zh) * 2006-07-04 2009-08-19 阿斯利康(瑞典)有限公司 新型吡啶类似物
JP2009542641A (ja) * 2006-07-04 2009-12-03 アストラゼネカ アクチボラグ 新規ピリジン類縁体
US20090286834A1 (en) * 2006-07-04 2009-11-19 Astrazeneca Ab Pyridine Analogues VI

Also Published As

Publication number Publication date
JP2009501216A (ja) 2009-01-15
AU2006267148A1 (en) 2007-01-18
WO2007008140A1 (en) 2007-01-18
EP1904474A1 (en) 2008-04-02
RU2008101924A (ru) 2009-08-20
TW200726758A (en) 2007-07-16
NO20076682L (no) 2008-03-05
IL188293A0 (en) 2008-04-13
EP1904474A4 (en) 2010-06-16
CA2614726A1 (en) 2007-01-18
KR20080039405A (ko) 2008-05-07
US20080312208A1 (en) 2008-12-18
UY29667A1 (es) 2007-02-28
MX2008000470A (es) 2008-03-11
ECSP088140A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
AR054632A1 (es) ANALOGOS DE PIRIDINA, COMPOSICIONES QUE LOS CONTIENEN Y PROCESOS PARA SU PREPARACIoN
AR061651A1 (es) Analogos de piridina ii
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
AR056838A1 (es) Derivados de 1,2,5-tiadiazol
AR040336A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR070995A1 (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe
AR057986A1 (es) Compuesto heterociclico y su uso farmaceutico
AR056548A1 (es) Derivados de sulfonamidas, composiciones farmaceuticas y sus usos
AR048241A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
AR051215A1 (es) Derivados de quinazolina
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR069772A1 (es) Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria.
AR056109A1 (es) Derivados de tiazolopiridina como activadores de la actividad de glucoquinasa
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR066561A1 (es) Derivados de imidazol, composiciones farmaceuticas y usos
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR079236A1 (es) Derivados de ciclohexano y usos de los mismos
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal